Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Interventional
Official Title: A Phase II Trial of AZD6244 (NSC #748727) in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Brief Summary: This phase II trial is studying the side effects and how well selumetinib works in treating patients with recurrent low-grade ovarian cancer. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.